Associated Papers
Effects of ABC transporter polymorphism on the pharmacokinetics of pentoxifylline and its active metabolites in healthy Chinese subjects.
Guo L et al.
European Journal of Clinical Pharmacology, 2026
Influence of CYP2D6, CYP3A, and ABCG2 Genetic Polymorphisms on Ibrutinib Disposition in Chinese Healthy Subjects.
Fu K et al.
Pharmaceuticals (basel, Switzerland), 2025
Association of Functional Genetic Variations in Uric Acid Transporters with the Risk of Idiopathic Male Infertility: A Genetic Association Study and Bioinformatic Analysis.
Karimian M et al.
Biochemical Genetics, 2025
Association of ABCG2 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.
Sharawi ZW et al.
Pharmaceuticals (basel, Switzerland), 2025
rs2231142 (421 C>A, Q141K) Is More Functionally Influential than rs2231137 (34 G>A, V12M) on Anticancer Drug Resistance Mediated by the ABCG2 Haplotype In Vitro.
Yamashita M et al.
International Journal of Molecular Sciences, 2025
Pathogenic germline variants in small cell lung cancer: A systematic review and meta-analysis.
Ul Haq S et al.
Hgg Advances, 2025
Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.
Yao ZW et al.
Clinical and Translational Science, 2025
Exploring the effect of intracellular loop 1 genetic variants in human ABCG2 on transport activity and protein abundance.
Sjöstedt N et al.
Drug Metabolism and Pharmacokinetics, 2025
Effects of ABCG2 421C > A genetic polymorphism on the pharmacokinetics of rivaroxaban in healthy Chinese subjects.
Guo L et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2025
Safety of teriflunomide in Chinese adult patients with relapsing multiple sclerosis: A phase IV, 24-week multicenter study.
Quan C et al.
Chinese Medical Journal, 2025
Variants of the ABCG2 gene in Mexican mestizo patients with prostate cancer.
Mimendi-Aguilar GM et al.
Cellular and Molecular Biology (noisy-le-grand, France), 2025
The role of ABCG2 in health and disease: Linking cancer therapy resistance and other disorders.
El-Ashmawy NE et al.
Life Sciences, 2025
Novel Genetic Loci in Early-Onset Gout Derived From Whole-Genome Sequencing of an Adolescent Gout Cohort.
Ji A et al.
Arthritis & Rheumatology (hoboken, N.j.), 2025
SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin-induced rhabdomyolysis: A case report.
Medwid S et al.
British Journal of Clinical Pharmacology, 2025
Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients.
Akarapredee N et al.
Plos One, 2025
Discovery and prioritization of genetic determinants of kidney function in 297,355 individuals from Taiwan and Japan.
Chen HL et al.
Nature Communications, 2024
Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
Mykkänen AJH et al.
Clinical Pharmacology and Therapeutics, 2024
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol.
Kasten A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis.
Morau MV et al.
Genes, 2024
Placental efflux transporters and antiseizure or antidepressant medication use impact birth weight in MoBa cohort.
Hernandez MH et al.
Iscience, 2024
ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity.
Singh H et al.
Molecular Genetics & Genomic Medicine, 2024
Biochemical characterization of Jr(a-) blood type-related ABCG2 variants: Arg147Trp and Ser572Arg disrupt the plasma membrane localization of ABCG2.
Toyoda Y et al.
Transfusion, 2024
When the same treatment has different response: The role of pharmacogenomics in statin therapy.
Zheng E et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Examining the Association of Rare Allelic Variants in Urate Transporters SLC22A11, SLC22A13, and SLC17A1 with Hyperuricemia and Gout.
Vávra J et al.
Disease Markers, 2024
Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics.
Korošec Hudnik L et al.
Frontiers in Psychiatry, 2024
Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.
Zheng Y et al.
Frontiers in Pharmacology, 2024
Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk.
Hao Ing Y et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
In vitro identification of decreased function phenotype ABCG2 variants.
Suominen L et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2023
Hemolytic disease of the newborn due to anti-Jra from a Chinese mother with one novel and one classic heterozygous mutation.
Xiao J et al.
Transfusion Medicine (oxford, England), 2023
Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.
Yow HY et al.
Asian Biomedicine : Research, Reviews and News, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM et al.
Eclinicalmedicine, 2023
Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer.
Yamazaki M et al.
Anticancer Research, 2023
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
Lehtisalo M et al.
British Journal of Clinical Pharmacology, 2023
The pharmacogenomic landscape of an Indigenous Australian population.
Samarasinghe SR et al.
Frontiers in Pharmacology, 2023
Comparative analysis of MTP -493G/T and ABCG2 34G/A polymorphisms and theirs expression in HIV-associated lipodystrophy patients.
Singh H et al.
Frontiers in Cardiovascular Medicine, 2023
A meta-analysis and experimental data for multidrug resistance genes in breast cancer.
Zaib S et al.
African Health Sciences, 2022
Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia.
Alarcón-Payer C et al.
Journal of Personalized Medicine, 2022
Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R et al.
International Journal of Molecular Sciences, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2022
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á et al.
Pharmaceutics, 2022
Pharmacogenetics of Drugs Used in the Treatment of Cancers.
Franczyk B et al.
Genes, 2022
An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice.
Wang CW et al.
Frontiers in Pharmacology, 2022
Prediction of various blood group systems using Korean whole-genome sequencing data.
Hyun J et al.
Plos One, 2022